8-K: 2seventy bio Reports Q1 2024 Results, Abecma Commercial Launch Underway Following FDA Approval

2seventy bio announced its first quarter 2024 financial results, highlighting the FDA approval of Abecma for earlier lines of multiple myeloma treatment and a strategic realignment focusing on Abecma's commercialization.

Summary

• 2seventy bio reported a net loss of $52.7 million for the first quarter of 2024, compared to a net loss of $47 million in the same period of 2023.
• Total revenue for the quarter was $12.4 million, a decrease from $41.6 million in the first quarter of 2023.
• Abecma U.S. commercial revenue, as reported by Bristol Myers Squibb (BMS), was $52 million for the quarter.
• The company completed the divestiture of its R&D pipeline to Regeneron, streamlining its focus to Abecma.
• 2seventy bio ended the quarter with $181.4 million in cash, cash equivalents, and marketable securities, projecting a cash runway beyond 2027.
• The FDA approved Abecma for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy on April 4, 2024.
• The company anticipates that Abecma's commercial performance will be impacted by competitive dynamics but expects a return to growth in the second half of 2024.
• Research and development expenses decreased to $43.9 million from $68.2 million year-over-year.
• Selling, general, and administrative expenses decreased to $12.7 million from $20.7 million year-over-year.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the FDA approval and strategic realignment, but tempered by the reported net loss and revenue decline. The focus on Abecma and cost-cutting measures are positive, but the competitive landscape and risks associated with the therapy are concerning.

Positives

• The FDA approval of Abecma for earlier lines of therapy significantly expands the potential market.
• The divestiture of the R&D pipeline allows the company to focus resources on Abecma's commercialization.
• The company has a strong cash position with a runway projected beyond 2027.
• The transition to sLVV manufacturing is expected to support increased demand for Abecma.
• The company anticipates a return to growth for Abecma in the second half of 2024.
• The company has reduced operating expenses in research and development and selling, general and administrative areas.

Negatives

• The company reported a net loss of $52.7 million for the first quarter of 2024.
• Total revenue decreased significantly compared to the same period last year.
• The company experienced a collaborative arrangement loss of $1.2 million related to the collaboration with BMS.
• The company reported a loss on assets held for sale of $5.0 million.
• The company anticipates that Abecma's commercial performance will be impacted by competitive dynamics.

Risks

• The commercial success of Abecma is subject to competitive dynamics.
• The company's strategic realignment may not achieve the anticipated cost savings or may cause disruptions.
• The company may be unable to manage operating expenses or cash use effectively.
• There are risks associated with the manufacturing and supply of Abecma.
• The company is subject to risks related to the safety and efficacy of Abecma, including Cytokine Release Syndrome, Neurologic Toxicities, and other adverse reactions.
• The company is subject to risks related to the development of secondary malignancies in patients treated with Abecma.

Future Outlook

The company anticipates a return to growth for Abecma in the second half of 2024 and expects to have a cash runway beyond 2027.

Management Comments

• In the first quarter of 2024, we have successfully completed a strategic re-alignment to focus exclusively on Abecma, seeking to impact many more patients in earlier lines and return to commercial growth, said Chip Baird, CEO, 2seventy bio.
• We have executed against the plan we described in January, completing the sale of our R&D business to Regeneron and obtaining FDA approval for Abecma in the earlier line setting.
• Going forward, we will have a streamlined cost structure that gives us time to return Abecma to growth with our partner, Bristol Myers Squibb.

Industry Context

The announcement reflects a strategic shift in the biotech industry towards focusing on core assets and commercialization, particularly in the competitive CAR T-cell therapy space. The FDA approval for earlier lines of therapy is a significant milestone for Abecma, positioning it to compete with other therapies in the multiple myeloma market.

Comparison to Industry Standards

• The $52 million in Abecma revenue is a key metric, but it's important to compare this to other CAR T-cell therapies like Johnson & Johnson's Carvykti, which has seen rapid growth in the same space.
• The company's cash runway beyond 2027 is a positive sign, but it needs to be evaluated against the burn rate and potential future capital needs compared to peers like Legend Biotech and other companies in the cell therapy space.
• The reduction in R&D expenses is a common strategy for companies focusing on commercialization, but it needs to be balanced against the need for future innovation and pipeline development compared to companies like Gilead and Novartis who have large R&D budgets.
• The collaborative arrangement loss of $1.2 million needs to be assessed against the overall profitability of the Abecma partnership with BMS, and compared to other similar co-development agreements in the industry.

Stakeholder Impact

• Shareholders may be concerned about the net loss and revenue decline, but encouraged by the FDA approval and strategic focus.
• Employees may experience changes due to the strategic realignment and cost-cutting measures.
• Patients may benefit from the expanded availability of Abecma for earlier lines of therapy.
• Suppliers and creditors may be impacted by the company's financial performance and strategic changes.

Next Steps

• The company will focus on the commercial launch of Abecma in earlier lines of therapy.
• 2seventy bio and BMS will continue to work together to restore growth for Abecma.
• The company will monitor the competitive dynamics in the market.
• The company will continue to manage its operating expenses and cash use.

Key Dates

Keywords

Abecma, Multiple Myeloma, CAR T-cell therapy, FDA Approval, Commercial Launch, Financial Results, Regeneron, Bristol Myers Squibb, Strategic Realignment, Cash Runway